Radha Singh

Experienced researcher adept in preclinical and clinical evaluation of health products, with strong proficiency in molecular biology, microbiology, biochemistry, and analytical techniques. Skilled in scientific and grant writing, laboratory management, collaborations, and timely execution of multidisciplinary projects. Passionate about translating research into real-world health innovations and fostering learning environments that promote scientific curiosity and growth.

• Conducted three clinical trials without CRO assistance.
• Isolated 18 novel antimicrobial compounds from endophytes.
• Filed two Indian patents for antibacterial compounds.
• Purified and characterized 16 pure compounds from actinobacterial metabolites.
• Qualified GATE (2012) and ASRB-NET (2018).
• First Prize, Best Oral Presentation, International Conference (JIIT, Noida).

• A Novel Benzopyrone Derivative from Streptomyces chrestomyceticus ADP4 Inhibits Growth and Virulence Factors of Candida albicans. Curr Microbiol. 2025;82(5):201. (IF 2.6)
• Immunomodulatory Action of Maharishi Amrit Kalash – A Scoping Review. Indo Global J Pharm Sci. 2025;15:1–15.
• A Novel Diterpene Derivative from S. chrestomyceticus ADP4 Inhibits Biofilm Formation in Candida spp.
• J Appl Microbiol (Accepted, 2024). (IF 4.3)
• Identification of a Decalin Derivative with Anti-Candida Activity from S. chrestomyceticus ADP4. Arch Microbiol. 2024. (IF 2.7)
• Scoping Review on ‘Maharishi Amrit Kalash’ for Cancer Prevention and Management. J Altern Integr Med. 2024. (IF 2.4)
• Phenyl Pentyl Ketone and m-Isobutyl Methoxy Benzoate as Broad-Spectrum Antimicrobials from S. chrestomyceticus ADP4. Indian J Microbiol. 2023. (IF 2.46)
• Anti-Candida Attributes and Drug-likeness of Compounds from S. chrestomyceticus ADP4. J Appl Microbiol. 2022;134(1). (IF 4.3)
• Differential Synthesis of Secondary Metabolites by S. chrestomyceticus under Nitrogen Modulation. Microorganisms (MDPI Proceedings), 2020.
• Isolation and Characterization of Streptomyces californicus ADR1 Producing Antimicrobial Metabolites. Microorganisms. 2020;8(6):929. (IF 4.1)
• Diversity and Applications of Endophytic Actinobacteria in Ecological Niches. Front Microbiol. 2018. (IF 5.6)
• Inhibition of S. aureus Biofilm by Metabolites of Streptomyces sp. ADR1. MOL2NET. 2018.
• Important Aspects of Postprandial Antidiabetic Drug Acarbose. Curr Top Med Chem. 2016. (IF 3.8)
• Endophytic Actinomycetes as Emerging Sources of Therapeutic Compounds. Indo Global J Pharm Sci. 2015.
• Gene Sequence Publication: 16S rRNA partial gene sequences of 9 endophytic actinobacteria (NCBI GenBank).
• Patent No. 202111034351 A – Issue No. 09/2023 (03/03/2023)
• Patent No. 202111034352 A – Issue No. 09/2023 (03/03/2023)
• Differential Synthesis of Secondary Metabolites by S. chrestomyceticus – International Electronic Conference on Microbiology (MOL2NET), 2020.
• Anti-Staphylococcus and Antioxidant Activities of S. californicus ADR1 – University of Mysore, 2019.
• Optimization and Characterization of Anti-Candida Activity – IIT-Delhi Sonipat, 2019.
• Inhibition of Biofilm Formation by Natural Product-Derived Compounds – BESCON, 2017.
• Anti-infective Activity of Endophyte ADR1 against MRSA – AMI Annual Conference, 2017.
• Endophytic Actinomycetes as Potential Therapeutic Agents – IC LIFE, JIIT Noida, 2014.

• Literature analysis: PubMed, NCBI, RCSB.
• Molecular tools: BioEdit, MEGA, AutoDock.
• Data analysis: GraphPad Prism, ChemDraw, T.E.S.T, ADME Swiss.
• Design tools: Inkscape.

GATE-2012